TXMD · TherapeuticsMD, Inc.

TherapeuticsMD’s Q1 2026 results mark a pivotal inflection point: the Company achieved its first quarterly net income ($103 thousand) since pivoting to a pure pharmaceutical royalty model in December 2022. This reversal from a $636 thousand net loss in Q1 2025 reflects both top-line growth—license revenue rose 84% year-over-year to $724 thousand, primarily under the Mayne License Agreement—and disciplined cost management, with operating expenses falling 13.6% to $1.45 million due to the absence of a prior-year write-off and reduced professional and share-based compensation costs. Critically, the press release confirms the Company has fully exited active R&D and commercial operations, now functioning solely as a royalty collector—a structural shift that eliminates recurring operational volatility but introduces dependency on licensee execution. The $8.4 million cash balance provides runway, though no forward guidance is provided; instead, management emphasizes ongoing evaluation of strategic alternatives—including acquisition, merger, or asset sale—with explicit disclaimers about timing, certainty, or outcome. Given the magnitude of the earnings inflection, the permanence of the business model change, and the material uncertainty surrounding potential strategic transactions, this filing carries HIGH materiality for investors assessing viability, valuation, and near-term catalysts. Risks cited—including disputes with Mayne Pharma, reliance on third-party commercialization, and going-concern uncertainty—remain embedded in the forward-looking statements and SEC risk factors, underscoring that profitability remains nascent and contingent on external factors beyond TherapeuticsMD’s control.